Rigel Pharmaceuticals, Incorporated

Aerovance, Inc.

Stephanie Yung

Rajinder Paul Singh

Hui Li

Donald G Payan

Esteban Masuda

Kin Tso

Clark Qun Pan

Jeffrey M Greve

Taisei Kinoshita

Steve Roczniak

Malinda Longphre

Tarikere Gururaja

Adrian Tomkinson

Teresa Mo-Fun Wong

Rongxian Ding

David C Boisvert

Kathy Delaria

Elise Burmeister-Getz

Methods for treating an inflammatory disorder and for inhibiting the production of IL-23 using 2,4-pyrimidinediamine compounds represented by formula (I): 

Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds

2,4-Pyrimidinediamine compounds represented by formula (I), methods for preparing the same and methods for treating an inflammatory disorder and for inhibiting the production of IL-23 and/or stimulating the production of IL-10 using the same: 

2,4-pyrimidinediamine compounds for treatment of inflammatory disorders

This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.

Modified IL-4 mutein receptor antagonists

Growing community of inventors

San Francisco, CA, United States of America

Stephanie Yung